Remove 2018 Remove Clinic Remove Diagnostic
article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

article thumbnail

Diagnosing Pediatric Crohn Disease With Radiomic and Clinical Data

Imaging Technology

milla1cf Wed, 08/02/2023 - 19:58 August 2, 2023 — An accepted manuscript published in the American Journal of Roentgenology (AJR) found that deploying a radiomic-based model with T2-weighted MRI data could increase diagnostic accuracy for pediatric Crohn disease (CD). Dillman et al.’s and accuracy of 89.6%. and accuracy of 89.6%.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BERT-based AI poised for use in radiology

AuntMinnie

Its implementation in radiology holds potential for enhancing diagnostic precision, expediting report generation, and optimizing patient care,” the group wrote. BERT (Bidirectional Encoder Representations from Transformers) is a natural language processing (NLP) foundation model introduced in 2018.

Radiology 122
article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil., The adverse reactions reported in ≥0.4%

article thumbnail

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Chief Executive Officer of Blue Earth Diagnostics.

article thumbnail

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 98
article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. One of this year's nominations for Most Influential Radiology Researcher is Erik Middlebrooks, MD, of the Mayo Clinic in Jacksonville, FL. He served in the U.S. He earned his medical degree from Washington University in St.